PointState Capital’s ProQR Therapeutics PRQR Stock Holding History

PointState Capital’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-173,500	Closed	-$3.76M	–	140
2014 Q4	$3.76M	Buy	+173,500	New	+$2.63M	0.06%	93

Other funds holding PRQR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PointState Capital's PRQR Position: Q1 2015 in Review

PointState Capital sold out of ProQR Therapeutics (PRQR) in Q1 2015, closing a stake of 173,500 shares — an estimated $3.76M sold.

PointState Capital first reported a position in PRQR in Q4 2014 and held it in 1 quarter. The position peaked at $3.76M in Q4 2014. 38 funds tracked by Wall St. Rank hold PRQR as of Q1 2015.

PointState Capital reported no remaining ProQR Therapeutics position as of Q1 2015 after selling out during the quarter.
PointState Capital sold 173,500 ProQR Therapeutics shares in Q1 2015, an estimated $3.76M.
PointState Capital first reported a position in ProQR Therapeutics in Q4 2014 and held it in 1 quarter.
PointState Capital's ProQR Therapeutics position peaked at $3.76M in Q4 2014.
38 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2015.

Based on PointState Capital's 13F filing for Q1 2015, filed 15 May 2015.